← Russell 3000 cross-section

RXST RxSight, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$276m
Revenue TTM
$121m
Net income TTM
$-47m
Free cash flow
$-27m
Composite score
45.2
Sector rank
#2711

Valuation

P / E
EV / EBITDA
EV / sales
0.6
FCF yield
-9.84%
Earnings yield vs 10-yr
-21.71pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-38.8%
EBITDA margin
-42.6%
ROE
-17.8%
ROIC
-101.0%
Revenue growth
-17.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented: Revenue Recognition Product Sales The Company’s product revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. …RxSight, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →